This multicentric retrospective study of patients with RPS treated with neoadjuvant systemic therapy over a 10-year time span provides data to begin defining the role of neoadjuvant systemic therapy in RPS and help to optimize the design of an upcoming prospective trial. The results showed that partial responses were possible in almost a quarter of cases, whereas most tumors demonstrated stable disease; disease progression on systemic therapy was clearly associated with worse outcomes.

Find full article here.